The global market for uveitis treatment is anticipated to develop over the forecast period as a result of the high prevalence of uveitis. For instance, according to a paper published in Frontiers in Medicine on September 10, 2021, the Northern California research showed an incidence of 52.4 cases of uveitis per 100,000 person-years, but the Pacific Ocular Inflammation Study identified an incidence of 24.9 cases per year. Over the forecast period, the global market for uveitis treatment is anticipated to develop because to the rise in Autoimmune illnesses ' high occurrence. For instance, estimates from the department of pathology at John Hopkins University imply that all autoimmune disorders combined impact about 3% of the U.S. population annually, or roughly 10 million individuals.
The global Uveitis Treatment Market is estimated to be valued at US$ 710.0 Mn in 2022 and is expected to exhibit a CAGR of 5.3% over the forecast period (2022-2030).
Key Leaders in the Uveitis Treatment Industry:
1. AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide since 2012. It is headquartered in North Chicago and operational in more than 70 countries. AbbVie and HotSpot Therapeutics, Inc., in December, 2022 announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases
2. Novartis AG.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Novartis in December, 2022 announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy.
3. Bausch Health Companies Inc.
Bausch Health Companies Inc. is a global company that develops, manufactures and markets a range of pharmaceuticals.The headquarters are located in Quebec, Canada and is operational in more than 90 countries
4. Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. In June, 2022 Galapagos NV CellPoint and AboundBio announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly broadening its portfolio and capabilities.
5. EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders. EyePoint Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts. In January, 2023 EyePoint Pharmaceuticals, Inc., announced that it has entered into a lease agreement to design and construct a 40,000-square-foot manufacturing facility in Northbridge, Massachusetts to support the global manufacturing of programs, including EYP-1901 and YUTIQ.
6. Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
7. Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
8. Bausch & Lomb Incorporated
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The company was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. In February, 2023 Bausch + Lomb Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).1 ML6710i is expected to be available for eye care professionals during the first half of 2023
9. Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries. Sanofi and Innate Pharma SA announced in December, 2022 an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.
10. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
*Definition - The central layer of the eye, the uvea, which is made up of the iris, cilliary body, and choroid, becomes inflamed when someone has uveitis.
